BioCentury
ARTICLE | Top Story

Anacor soars on Phase III dermatitis data

July 14, 2015 1:25 AM UTC

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) jumped $47.32 (56%) to $131.93 on Monday after its crisaborole ( AN2728) met the primary and secondary endpoints in two Phase III trials to treat atopic dermatitis. Anacor plans to submit an NDA for crisaborole in 1H16, and expects to launch the product in 1H17.

On a conference call, EVP and Chief Commercial Officer Vince Ippolito said crisaborole has the potential to exceed $1 billion in annual net revenues. While the price of crisaborole has not been determined, Ippolito said the company references the price of marketed topical treatments including Elidel pimecrolimus from Novartis AG (NYSE:NVS; SIX:NOVN) and Protopic tacrolimus from Astellas Pharma Inc. (Tokyo:4503) to calculate the candidate's sales projections. ...